Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBPBiotechnology
+$0.14 today
- Market cap
- $56.57M
- Beta
- 2.59
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$6.35
Volume 0.63M
Average 0.42M
CRBP Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $19.82M rose 26.7% year over year, behind the +76.4% change in trailing-twelve-month research & development. Sequentially, it rose 7.7% from the prior quarter. Over 3 fiscal years it compounded at +63.2% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +26.7% toward the trailing-twelve-month pace of +76.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 70.1M USD
- Year-over-year change
- +117.5%
- 4-year CAGR
- +17.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 70.1M | +117.5% |
| FY2024 | 2024-12-31 | 32.22M | +3.4% |
| FY2023 | 2023-12-31 | 31.17M | +93.1% |
| FY2022 | 2022-12-31 | 16.14M | -55.7% |
| FY2021 | 2021-12-31 | 36.45M | — |
Research & Development vs competitors
How CRBP compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +76.4% is the 2nd highest of 10, against a peer median of -19.6%.
- Over three fiscal years its annual growth of +63.2% compares with a peer median of -5.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $114.68M USD | -37.7% | -16.4% | 622.7% | |
| LTM Mar 2026 | $74.27M USD | +76.4% | +63.2% | — | |
| LTM Mar 2026 | $65.43M USD | +123.8% | +118.4% | — | |
| LTM Mar 2026 | $58.35M USD | -32.7% | +9.5% | — | |
| LTM Mar 2026 | CHF 46.97M CHF | -1.7% | -7.5% | — | |
| FY2025 | €43.62M EUR | -16.1% | -5.5% | 1565.1% | |
| LTM Mar 2026 | $31.62M USD | -19.6% | +9.2% | 6022.3% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $23.84M USD | -29.5% | +13.5% | — |
| LTM Mar 2026 | $18.8M USD | -26.8% | -18.0% | 593.1% | |
| LTM Mar 2026 | $16.56M USD | +5.5% | -23.1% | 928.4% | |
| Peer median (excluding CRBP) | — | -19.6% | -5.5% | 928.4% | |
Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 881.71K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.64M | 1.49M | 0 | 600K | 0 |
| Gross Profit | (757.53K) | (1.49M) | 0 | (600K) | 0 |
| Gross Margin | -85.9% | — | — | — | — |
| Research & Development | 36.45M | 16.14M | 31.17M | 32.22M | 70.1M |
| Selling, General & Admin | 20.43M | 18.7M | 13.91M | 16.5M | 15.22M |
| Operating Expenses | 55.23M | 33.35M | 45.08M | 48.12M | 85.31M |
| Depreciation & Amortization | 1.64M | 1.49M | 641K | 600K | 233K |
| EBITDA | (42.17M) | (38.73M) | (40.11M) | (37.74M) | (78.3M) |
| EBITDA Margin | -4782.9% | — | — | — | — |
| Operating Income | (55.99M) | (34.84M) | (45.08M) | (48.72M) | (85.31M) |
| Operating Margin | -6350.1% | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 6.31M | 5.53M |
| Interest Expense | 1.83M | 2.13M | 2.92M | 1.87M | 0 |
| Other Income / Expenses | 10.35M | (7.51M) | 474K | 8.51M | 6.77M |
| Income Before Tax | (45.64M) | (42.35M) | (44.6M) | (40.21M) | (78.54M) |
| Pre-Tax Margin | -5176.4% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (45.55M) | (55.83M) | (44.6M) | (40.21M) | (78.54M) |
| Net Margin | -5166.4% | — | — | — | — |
| EPS (Basic) | (11.13) | (10.15) | (10.31) | (3.68) | (5.90) |
| EPS (Diluted) | (11.13) | (10.15) | (10.31) | (3.68) | (5.90) |
| Weighted Avg Shares | 4.1M | 4.17M | 4.33M | 10.92M | 13.32M |
| Weighted Avg Shares (Diluted) | 4.1M | 4.17M | 4.33M | 10.92M | 13.32M |
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
Intrinsic Alpha fair value
Locked
Current Price
$2.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.